Aims To compare the eff ects of two long-acting calcium antagonists of diff erent types on cardiovascular stress responses in hypertension.
Introduction
Increased cardiac output and heart rate at rest and adrenergic hyperreactivity to stress in patients with borderline hypertension [1] [2] [3] , as well as normotensive off spring of hypertensive patients 4 , have characterized the pathophysiological haemodynamic changes in the development of hypertension. In established hypertension, increased peripheral resistance rather than increased cardiac output is characteristic 5 . The increased pressure workload induces adaptive changes in the endothelium, the vascular smooth muscle and the extracellular matrix of vessels and the heart 6, 7 . Development of left ventricular hypertrophy adds to the increased cardiovascular risk in hypertensive patients 8 . Furthermore, increased blood pressure and heart rate responsiveness during stress could trigger myocardial ischaemia and infarction due to inability to supply oxygen during this high demand at increased workload 9, 10 . The incidence of ischaemic events follows a pa ern similar to rises in heart rate and blood pressure 11, 12 . Thus, drugs that would reduce cardiac load both at rest and during exertion could be benefi cial in hypertension.
Calcium antagonists are widely used to treat hypertension. Although the blood pressure reducing effi cacy of diff erent types of calcium antagonists is comparable, their mechanisms of action are not the same. While dihydropyridines induce peripheral vasodilatation and have li le or no eff ect on myocardial contractility and sinus node automaticity, nondihydropyridines have less infl uence on peripheral vascular smooth musculature and direct eff ects on cardiac inotropy and chronotropy 13, 14 . The aim of the present study was to compare the eff ects of a long acting dihydropyridine (amlodipine) and a phenylalkylamine (verapamil) on cardiovascular stress responses by noninvasive methods during isometric handgrip and cold pressor stress tests in patients with mild to moderate hypertension. This paper was presented as an abstract at the Eighteenth Scientifi c Meeting of the International Society of Hypertension in Chicago, August 2000.
Methods
Study design and subjects. The study was a double-blind randomized cross-over comparison of verapamil Sustained Release (SR, 240 mg) and amlodipine (5 mg), corresponding to the registered and recommended starting dosage of these drugs in The Netherlands. All patients were at least 18 years of age and had mild to moderate hypertension, defi ned as a diastolic blood pressure between 95 and 110 mmHg on at least three occasions. In these patients, either hypertension was newly diagnosed, or current antihypertensive treatment did not meet therapeutic goals. Patients were excluded if secondary hypertension was suspected or if they had had a recent cardiovascular event. Seven centres in six European Community countries participated. Informed consent was obtained from all patients. The local ethics commi ees at each participating hospital approved the protocol.
At the fi rst patient visit, any antihypertensive treatment was stopped and 4 weeks of placebo treatment was started. Si ing blood pressure was measured three times aft er 10 min of rest with 2 min intervals. Randomization to sequence 1 (8 weeks of verapamil−4 weeks of placebo −8 weeks of amlodipine) or 2 (8 weeks of amlodipine −4 weeks of placebo−8 weeks of verapamil) followed at the second visit if diastolic blood pressure was ≥ 95 and ≤110 mmHg and systolic blood pressure ≤180 mmHg. The fi rst placebo period was open, both active drug periods were double-blind and the second placebo period was single-blind. All tablets were taken in the evening.
Study procedures.
All tests were performed in the morning in a warm, quiet room. Patients refrained from eating, smoking and drinking alcohol, coff ee and tea that day. A Finapres (Ohmeda 2300, Englewood, Colo., USA) blood pressure monitor was a ached to the third fi nger of the patient's right hand. Ten minutes aft er insertion of a catheter in an antecubital vein of the left arm, heart rate and si ing sphygmomanometric blood pressure were measured and the Finapres blood pressure monitoring was started. Aft er another 10 min of supine rest, the isometric handgrip test was performed; the patient had to squeeze a dynamometer at 30% of the predetermined maximum strength, during 3 min, with his left hand. Aft er a recovery period of 10 min, the cold pressor test was performed; the left hand was immersed in ice-water (0-4° C) for 2 min. Then, a second recovery period of 10 min followed. Since the autonomic nervous system is very much infl uenced by mental stress, the sole purpose of the fi rst visit was to get the patient acquainted with the study procedures.
Venous blood (6 ml) was sampled in a prechilled EGTA-glutathion tube 1 min before and 1 min aft er both handgrip and cold pressor. Plasma noradrenaline concentrations were determined by electrochemical detection aft er high-pressure liquid chromatography in a central laboratory (Analytico, Breda, the Netherlands) for all centres.
Beat to beat systolic (SBP) and diastolic blood pressure (DBP) and heart rate (HR) were obtained from the RS232 interface of the Finapres and stored on a personal computer. Rate-pressure product was calculated by multiplying HR by SBP. Mean SBP, DBP, HR and rate-pressure product were determined for consecutive periods of 20 s. The changes in SBP, DBP, HR and rate-pressure product were calculated for every minute.
Statistical analysis. The primary endpoint of this analysis was defi ned as the diff erence in increase of the rate-pressure product with verapamil and amlodipine during the stress tests. Sample-size calculation was based on the rate-pressure product responses to diff erent types of stress of a recent trial comparing verapamil and amlodipine in hypertensive subjects 15 . Anticipating a standard deviation of 1100, 134 evaluable patients were needed to detect a diff erence of 500 mmHg × beats min -1 in a 2-sided t-test for α = 0.05 with 95% power.
A mixed ancova model was defi ned to test the null hypothesis of no diff erence between both treatments. Period, treatment and centre were defi ned as fi xed factors, the placebo period preceding the active drug as covariate and patient within centre as random eff ect. Bonferroni's correction for multiple comparisons was used. A P value < 0.05 in the 2-sided test was considered statistically signifi cant. A Wilcoxon test was used for all parameters that had a skewed distribution and could not be normalized by log transformation. Student's t-test was performed for all parameters, to check for any diff erences between the fi rst and second placebo period. A secondary model tested the possibility of a carry-over eff ect. All data are shown as mean±s.e.mean. Diff erences between both drugs are shown as mean with 95% CI or natural log (LN) mean with 95% CI for parameters that were log transformed before analysis.
Results
One hundred 45 patients were randomized at the second visit. Patient characteristics at randomization are summarized in Table 1 . Twentytwo patients later dropped out of the study due to adverse events, lack of compliance and withdrawal of their consent. The data were analysed according to the intention-to-treat (ITT) principle: all patients that had used at least one tablet of active treatment entered the ITT-population. The design of the study does not allow an unbiased assessment of the relation between adverse events and study drugs. The adverse events with a probable relation with the drugs (verapamil/amlodipine) were most frequently common side-eff ects: headache (2/1), dizziness (3/1), palpitations (0/1), constipation (1/1) and peripheral oedema (2/1). In addition, three generalized allergic responses to verapamil that faded aft er withdrawal were observed. The mean compliance, assessed by tablet count, was > 95% for all treatments. Because no signifi cant difference between both placebo periods existed for any parameter, the mean of both is presented.
Sphygmomanometric blood pressure and heart rate. During placebo, mean systolic and diastolic blood pressure were 153 ± 1 and 100 ± 1 mmHg, respectively. Both were equal aft er verapamil and amlodipine treatment: SBP 139 ± 2 vs 138 ± 2 mmHg, diff erence 0.86, 95% CI (−1.65, 3.38), P=0.50 and DBP 91 ± 1 vs 91 ± 1 mmHg, diff erence 0.43, 95% CI . Heart rate was lower with verapamil than with amlodipine: 65 ± 1 vs 69 ± 1 beats min -1 , diff erence −4.0, 95% CI (−6.6, −2.7), P<0.0001.
Haemodynamic responses to handgrip and cold pressor. SBP, DBP, HR and rate-pressure product responses to handgrip and cold pressure are depicted in Figures 1 and 2 . Before both tests, SBP and DBP were not diff erent with verapamil and amlodipine; HR and rate-pressure Figure 2. Mean ± s.e. mean for blood pressure, heart rate and rate pressure product during and aft er 2 min of cold pressor (CP), for segments of 20 s. For the delta systolic blood pressure and delta rate pressure product the change from before the test are shown for each minute. *P<0.01, **P<0.00001, for verapamil vs amlodipine. *, placebo; , verapimil; , amlodipine.
product were signifi cantly lower with verapamil compared to amlodipine (P<0.0001 and P=0.002, respectively). Handgrip. During 3 min handgrip, SBP, DBP, HR and rate-pressure product increased signifi cantly with both drugs (P<0.0001 for all). SBP was signifi cantly lower with verapamil compared with amlodipine during the last 40 s of the test (aft er 3 min handgrip: 169 ± 3 vs 177 ± 4 mmHg, natural log diff erence 0.048, 95% CI (0.013, 0.083), P<0.01). The diff erence in DBP did not reach statistical signifi cance (aft er 3 min handgrip: 100 ± 2 vs 103 ± 3 mmHg, natural log diff erence 0.037, 95% CI (−0.006, 0.079), P=0.09). HR and rate-pressure product remained signifi cantly lower during and aft er the test with verapamil compared with amlodipine (aft er 3 min handgrip: HR 71 ± 1 vs 75 ± 1 beats min , diff erence 0.5, 95% CI (0.1, 0.9), P<0.01). Cold pressor. During 2 min cold pressor, SBP, DBP, HR and rate-pressure product increased signifi cantly with both drugs (P<0.0001 for all). With verapamil, SBP was signifi cantly lower from 40 s aft er the start of cold pressor until 3 min and 20 s aft er the test, compared to amlodipine (aft er 2 min cold pressor: 174 ± 4 vs 184 ± 4 mmHg, natural log diff erence 0.059, 95% CI (0.020, 0.099), P<0.01). DBP was signifi cantly higher with amlodipine compared with verapamil during the recovery period, during the third minute aft er the test. HR and rate-pressure product remained signifi cantly lower during and aft er the test with verapamil compared with amlodipine (aft er 2 min cold pressor: HR 67 ± 1 vs 72 ± 1 beats min -1 , natural log diff erence 0.069, 95% CI (0.043, 0.095), P<0.0001; rate-pressure product 11.6 ± 0.3 vs 13.2 ± 0.4 × 10 3 mmHg × beats min -1 , natural log diff erence 0.13, 95% CI (0.08, 0.19), P<0.0001). The increase in rate-pressure product was signifi cantly smaller with verapamil compared with amlodipine during the second minute of cold pressor (aft er 2 min cold pressor: 3.2 ± 0.2 vs 3.9 ± 0.3 × 10 3 mmHg × beats min -1 , diff erence 0.7, 95% CI (0.2, 1.1), P<0.01).
Plasma noradrenaline before and aft er handgrip and cold pressor (Table 2) . Before and aft er the handgrip as well as before and aft er the cold pressor test, plasma noradrenaline concentrations were higher with amlodipine compared with verapamil (P<0.001, P<0.001, P<0.001 and P=0.01). The increases in plasma noradrenaline concentration aft er both tests were not diff erent between the drugs.
Discussion
This study demonstrates that the eff ects of the long-acting dihydropyridine amlodipine and the phenylalkylamine verapamil on cardiovascular stress responses to exertion are markedly diff erent, whereas the reduction in resting blood pressure by the two drugs is similar. Calcium antagonists reduce blood pressure mainly by decreasing peripheral resistance. We found a similar reduction in blood pressure by verapamil and amlodipine at rest. This is in agreement with a study of Nazarro et al. 15 in 23 hypertensive patients that reported an equal reduction of blood pressure with verapamil and amlodipine after 4 weeks treatment. Furthermore, they found both drugs equally reduced peripheral resistance. The blood pressure reducing effi cacy at rest therefore seems to be the same for both drugs. However, the eff ects on resting rate-pressure product and heart rate are diff erent. We found that verapamil reduced resting rate-pressure product while amlodipine did not. This resulted from reduction in resting heart rate by verapamil, which directly eff ects sinus node automaticity 16 . During stress, the eff ects of verapamil and amlodipine on haemodynamics showed even more contrasts. Blood pressure lowering efficacy during handgrip in hypertensive patients has been reported with both verapamil 17 and amlodipine 18 . However, the present study also shows diminished systolic blood pressure and rate-pressure product . Isometric handgrip is a potent α-adrenergic stimulus. Verapamil has been shown to bind to the α-adrenergic receptor 19 . Furthermore, verapamil might directly inhibit presynaptic release of noradrenaline 20, 21 . However, although plasma noradrenaline concentrations before and aft er isometric handgrip were lower with verapamil compared with amlodipine, the increase in plasma noradrenaline concentration during handgrip was not diff erent in our study.
The cold pressor test is less frequently used to study the eff ects of calcium antagonists on cardiovascular stress responses in hypertension. Both handgrip and cold pressor test increase sympathetic outfl ow and peripheral resistance that results in an increase in blood pressure. The blood pressure and heart rate responses to handgrip showed a linear increase through time in our study ( Figure 1 ). In contrast, the cold pressor test induced changes which exhibited a hyperbolic time course. However, the eff ects of verapamil and amlodipine showed interesting contrasts. Verapamil blunted the systolic blood pressure, heart rate and rate-pressure product response during cold pressor compared to amlodipine. The change in rate-pressure product was lower with verapamil although the diff erence in systolic blood pressure response did not reach statistical signifi cance. In an earlier study of 13 hypertensive patients, verapamil reduced systolic blood pressure but not the increase in systolic blood pressure during cold pressor compared with placebo 22 . Although the present study showed a clear reduction in blood pressure and rate-pressure product responses to stress and a reduction of plasma noradrenaline at rest and aft er stress with verapamil compared with amlodipine, the potential advantage of these observations in the treatment of hypertension remains to be confi rmed. Still, the present study may have clinical implications. Firstly, the higher effi cacy of verapamil in reducing blood pressure during exertion suggests that its antihypertensive eff ect is more preserved during normal daily activities that oft en contain isometric handgrip. Secondly, the reduction in rate-pressure product at rest and during exertion and the smaller increase in rate-pressure product during exertion with verapamil should decrease myocardial oxygen consumption 23 at rest and during stress.
This cardioprotective eff ect of verapamil could be especially useful in patients with associated coronary artery disease, as supported by a study of 551 patients with chronic stable angina, in whom verapamil reduced the total duration of ischaemic episodes, in contrast to amlodipine which increased the total duration of ischaemic episodes 24 . The DAVIT-II study showed a reduction in major cardiovascular events in post myocardial patients without heart failure by verapamil compared with placebo 25 . However, the use of a rate-limiting drug as primary prevention of ischaemic events remains speculative. To determine whether the favourable eff ects of verapamil on blood pressure reactivity and heart rate would translate into improved prognosis, a large outcome study in hypertensive patients is needed.
We conclude that verapamil is more eff ective in reducing blood pressure and rate-pressure product responses to stress compared with amlodipine, while resting blood pressure is equally reduced by both. Although plasma noradrenaline is lower with verapamil at rest and aft er stress, the increase during stress is not diff erent compared with amlodipine.
